Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study

Trial Profile

Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Olaparib (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
    • 20 Jan 2018 Results of pool data from two parallel phases II trials (NCT02677038 and NCT02511223) assessing the efficacy of olaparib in advanced PDAC with BRCAness, were presented at the 2018 Gastrointestinal Cancers Symposium.
    • 28 Sep 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top